DexCom, Inc. (NASDAQ:DXCM) released preliminary, unaudited results for the fourth quarter of 2025 on January 12. The company reported total revenue of approximately $1.260 billion, an increase of 13% compared to the same period in 2024. U.S. revenue is projected to be around $892 million, showing 11% growth.
The company ended 2025 with revenue exceeding the high end of its guidance. It also launched its latest sensor technology, the G7 15 Day system. DexCom stated that clinical momentum continues to build in the continuous glucose monitoring category.
For 2026, DexCom expects total revenue to be between $5.16 billion and $5.25 billion. This represents an anticipated growth of approximately 11% to 13% over 2025. The outlook considers factors including sensor volume growth, the rollout of Stelo, further international expansion, and broader market dynamics.
DexCom is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring systems. The company looks forward to extending its growth through continued innovation and evidence generation in 2026.